Burroughs Wellcome using Abbott's ADD-Vantage
Executive Summary
B-W to market injectable drugs as part of Abbott's ADD-VANTAGE I.V. drug admixture system for drugs that are not stable in solution for more than 24 hours. Lilly entered into a similar agreement with Abbott in June ("The Pink Sheet" June 25, T&G-5). Abbott anticipates an early 1985 launch date for both product lines